Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819465 · ClinicalTrials.gov registry record · Phase 1
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
A Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT03819465: Active Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca.
NCT03819465 is a Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 175 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03819465, a Phase 1 study of Metastatic Non-Small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Primary Outcome
Assessment of safety and tolerability of each treatment arm
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Durvalumab
- DRUG Danvatirsen
- DRUG Oleclumab
- DRUG MEDI5752
Study Locations (20)
Other
- Research Site - Salzburg
- Research Site - Vienna
- Research Site - Edegem
- Research Site - Bialystok
- Research Site - Bydgoszcz
- Research Site - Gdansk
- Research Site - Grudziądz
- Research Site - Lodz
- Research Site - Olsztyn
- Research Site - Tomaszów Mazowiecki
- Research Site - Warsaw
- Research Site - Wroclaw
- Research Site - Krasnoyarsk
- Research Site - Moscow
- Research Site - Saint Petersburg
- Research Site - Saint Petersburg
- Research Site - Cheongju-si
Iowa
- Research Site - Iowa City
Pennsylvania
- Research Site - Pittsburgh
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2026-03-26 |
| Phase | Phase 1 |
What the registry record for NCT03819465 still lists
NCT03819465 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher).
The record links to 1 condition, with Metastatic Non-Small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Pemetrexed is the first listed.
NCT03819465 names 20 study sites across 4 states, led by Other, Iowa, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03819465 about?
NCT03819465 is a clinical study titled "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC". This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT03819465?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2018-12-27. Estimated completion is 2026-03-26.
What conditions does trial NCT03819465 study?
This clinical trial studies the following conditions: Metastatic Non-Small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT03819465?
The interventions under investigation include: Pemetrexed (DRUG), Durvalumab (DRUG), Danvatirsen (DRUG), Oleclumab (DRUG), MEDI5752 (DRUG).
Who is sponsoring clinical trial NCT03819465?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03819465 being conducted?
This trial has 20 study locations across Iowa, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03819465's enrollment target sits among peer trials
175 319th of 2000 higher than 1,679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI